File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.bbmt.2015.08.013
- Scopus: eid_2-s2.0-84947493926
- PMID: 26278046
- WOS: WOS:000364981700017
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Escalation to High-Dose Defibrotide in Patients with Hepatic Veno-Occlusive Disease
Title | Escalation to High-Dose Defibrotide in Patients with Hepatic Veno-Occlusive Disease |
---|---|
Authors | |
Keywords | Defibrotide Hepatic veno-occlusive disease Hematopoietic cell transplantation |
Issue Date | 2015 |
Citation | Biology of Blood and Marrow Transplantation, 2015, v. 21, n. 12, p. 2148-2153 How to Cite? |
Abstract | © 2015 American Society for Blood and Marrow Transplantation. Hepatic veno-occlusive disease (VOD) is a serious complication of high-dose chemotherapy regimens, such as those used in hematopoietic cell transplantation recipients. Defibrotide is considered a safe and effective treatment when dosed at 25 mg/kg/day. However, patients who develop VOD still have increased mortality despite the use of defibrotide. Data are limited on the use of doses above 60 mg/kg/day for persistent VOD. In this prospective clinical trial 34 patients received escalating doses of defibrotide. For patients with persistent VOD despite doses of 60 mg/kg/day, doses were increased to a maximum of 110 mg/kg/day. Increased toxicity was not observed until doses rose beyond 100 mg/kg/day. Patients receiving doses between 10 and 100 mg/kg/day experienced an average of 3 bleeding episodes per 100 days of treatment, whereas those receiving doses >100 mg/kg/day experienced 13.2 bleeding episodes per 100 days (. P = .008). Moreover, dose reductions due to toxicity were needed at doses of 110 mg/kg/day more often than at lower doses. Defibrotide may be safely escalated to doses well above the current standard without an increase in bleeding risk. However, the efficacy of this dose-escalation strategy remains unclear, because outcomes were similar to published cohorts of patients receiving standard doses of defibrotide for VOD. |
Persistent Identifier | http://hdl.handle.net/10722/294510 |
ISSN | 2022 Impact Factor: 4.3 2020 SCImago Journal Rankings: 2.301 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Triplett, Brandon M. | - |
dc.contributor.author | Kuttab, Hani I. | - |
dc.contributor.author | Kang, Guolian | - |
dc.contributor.author | Leung, Wing | - |
dc.date.accessioned | 2020-12-03T08:22:54Z | - |
dc.date.available | 2020-12-03T08:22:54Z | - |
dc.date.issued | 2015 | - |
dc.identifier.citation | Biology of Blood and Marrow Transplantation, 2015, v. 21, n. 12, p. 2148-2153 | - |
dc.identifier.issn | 1083-8791 | - |
dc.identifier.uri | http://hdl.handle.net/10722/294510 | - |
dc.description.abstract | © 2015 American Society for Blood and Marrow Transplantation. Hepatic veno-occlusive disease (VOD) is a serious complication of high-dose chemotherapy regimens, such as those used in hematopoietic cell transplantation recipients. Defibrotide is considered a safe and effective treatment when dosed at 25 mg/kg/day. However, patients who develop VOD still have increased mortality despite the use of defibrotide. Data are limited on the use of doses above 60 mg/kg/day for persistent VOD. In this prospective clinical trial 34 patients received escalating doses of defibrotide. For patients with persistent VOD despite doses of 60 mg/kg/day, doses were increased to a maximum of 110 mg/kg/day. Increased toxicity was not observed until doses rose beyond 100 mg/kg/day. Patients receiving doses between 10 and 100 mg/kg/day experienced an average of 3 bleeding episodes per 100 days of treatment, whereas those receiving doses >100 mg/kg/day experienced 13.2 bleeding episodes per 100 days (. P = .008). Moreover, dose reductions due to toxicity were needed at doses of 110 mg/kg/day more often than at lower doses. Defibrotide may be safely escalated to doses well above the current standard without an increase in bleeding risk. However, the efficacy of this dose-escalation strategy remains unclear, because outcomes were similar to published cohorts of patients receiving standard doses of defibrotide for VOD. | - |
dc.language | eng | - |
dc.relation.ispartof | Biology of Blood and Marrow Transplantation | - |
dc.subject | Defibrotide | - |
dc.subject | Hepatic veno-occlusive disease | - |
dc.subject | Hematopoietic cell transplantation | - |
dc.title | Escalation to High-Dose Defibrotide in Patients with Hepatic Veno-Occlusive Disease | - |
dc.type | Article | - |
dc.description.nature | link_to_OA_fulltext | - |
dc.identifier.doi | 10.1016/j.bbmt.2015.08.013 | - |
dc.identifier.pmid | 26278046 | - |
dc.identifier.pmcid | PMC4639417 | - |
dc.identifier.scopus | eid_2-s2.0-84947493926 | - |
dc.identifier.volume | 21 | - |
dc.identifier.issue | 12 | - |
dc.identifier.spage | 2148 | - |
dc.identifier.epage | 2153 | - |
dc.identifier.eissn | 1523-6536 | - |
dc.identifier.isi | WOS:000364981700017 | - |
dc.identifier.issnl | 1083-8791 | - |